JACC:药物洗脱支架和金属裸支架的长期安全性

2015-06-11 崔倩 译 MedSci原创

背景:以往的荟萃分析研究了不同类型的药物洗脱支架(DES)和金属裸支架(BMS)的相对安全性和有效性;然而,这些荟萃分析的大多数试验的随访时间仅1年,因此,设备的长期相对安全性及有效性都是未知的。许多最近的研究报告扩展了随访资料。    意义:本研究旨在探讨以聚合物为基础的耐用DES的长期安全性和有效性,通过网络荟萃分析的手段分析结合有生物可降解聚合物的Biolimu

背景:以往的荟萃分析研究了不同类型的药物洗脱支架(DES)和金属裸支架(BMS)的相对安全性和有效性;然而,这些荟萃分析的大多数试验的随访时间仅1年,因此,设备的长期相对安全性及有效性都是未知的。许多最近的研究报告扩展了随访资料。
    
意义:本研究旨在探讨以聚合物为基础的耐用DES的长期安全性和有效性,通过网络荟萃分析的手段分析结合有生物可降解聚合物的Biolimus洗脱支架(BES)和BMS。
    
方法:通过搜索MEDLINE,EMBASE,和Cochrane数据库和国际会议的随机对照试验,对每种DES相互对比或与BMS进行比较。信息提取包括研究设计,入选和排除标准,样本特征和临床结果。
    
结果:研究人员对51项试验中共52158例随访时间≥3年的随机患者进行了分析。在平均随访3.8年时,钴铬合金依维莫司洗脱支架(EES)的死亡率、明确的支架内血栓形成(ST)和心肌梗死概率比BMS、紫杉醇洗脱支架(PES)、西罗莫司洗脱支架(SES)低;同时,ST比BES少。以磷酸胆碱为基础的佐他莫司洗脱支架具有比SES更低的明确诊断的ST发生率,比BMS和PES更低的心肌梗死率。所有使用DES的靶血管血运重建的比率都比BMS、钴铬合金EES、铂铬EES、SES低;同时,BES比PES具有较低的靶血管血运重建率。
    
结论:在平均随访3.8年间,与BMS相比,所有的DES表现出卓越的功效。在DES中,与第一代装置相比,第二代装置已经大大改善长期安全性和有效性。

原始出处:

Tullio Palmerini,Umberto Benedetto,Giuseppe Biondi-Zoccai,Diego Della Riva,et al.Long-Term Safety of Drug-Eluting and Bare-Metal Stents,JACC,2015.6.9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-26 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2016-04-30 hbwxf
  5. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 liuhongze175

    结果是必然的,减缓内皮化,减少再狭窄

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 children5656

    meta还是挺有意思的 学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1990264, encodeId=9feb199026458, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Tue Mar 01 03:00:00 CST 2016, time=2016-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998724, encodeId=51a01998e24f1, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Fri Nov 27 12:00:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29554, encodeId=2f452955421, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:41:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853360, encodeId=877a1853360e8, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Apr 30 00:00:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310462, encodeId=080a131046238, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325050, encodeId=f4ea13250500c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 12 15:00:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27218, encodeId=d2eb2e21896, content=结果是必然的,减缓内皮化,减少再狭窄, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfd71609590, createdName=liuhongze175, createdTime=Thu Jun 11 23:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27153, encodeId=66e72e153e2, content=meta还是挺有意思的 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59781606904, createdName=children5656, createdTime=Thu Jun 11 20:33:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27021, encodeId=42822e021a7, content=只是有添加了一个重复的所谓研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jun 11 15:31:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 owlhealth

    只是有添加了一个重复的所谓研究。

    0

相关资讯

Int J Cardiol:多种药物洗脱支架致支架血栓的荟萃分析

支架血栓是行PCI治疗的潜在致死并发症之一。第一代的耐用药物洗脱支架已经明确与迟发或者超迟发支架血栓有关,可能继发于耐用多聚物诱导的炎症反应有关。第二代的药物洗脱支架含有生物相容性多聚物,其可降低血栓的发生率。第三代的药物洗脱支架NOBORI™为可降解生物相容性支架,因其在2007年的临床试验取得的成果,现同时作为一种抗增生药物广泛地被亚洲和欧洲国家所认可。 然而四项无限制患者的试验则出现了

如何权衡不同双联抗血小板疗程的利弊?

《内科学年鉴》(Ann Intern Med)于5月26日发表了一项有关双联抗血小板治疗的荟萃分析。该研究主要探索了药物洗脱支架介入术后双联抗血小板治疗的适宜疗程。 研究者指出虽然人们开展了大量双联抗血小板治疗(DAPT)的临床试验,但对于药物洗脱支架(DES)介入术后DAPT疗程存在争议,即DAPT疗程究竟长一些还是短一些更好。为解答这个问题,研

JACC:新型药物洗脱支架的治疗预后及相关预测因素(RESOLUTE研究)

新一代药物洗脱支架是介入心脏病学近年来的重要进展之一,但是在临床治疗中,我们尚缺乏此类支架的长期预后数据。同时,在预测因再狭窄或疾病进展而引起的再次血管重建方面,我们知之甚少。 因此,来自不同国家的研究者共同开展了此次研究。通过比较美敦力公司的Resolute佐他莫斯药物支架(R-ZES)与雅培公司的XIENCE V依维莫司洗脱支架(EES)的相关治疗数据,研究者给出了两者4年预后方面的差

Eur Heart J:R-ZES置入后早期中断DAPT与不良转归高风险相关

一项多国研究表明,在接受Resolute佐他莫司洗脱支架(R-ZES)置入的患者中,1个月内中断双重抗血小板治疗(DAPT)与不良转归高风险具有相关性;在1~12个月中断DAPT则与支架血栓形成(ST)和不良心血管转归低发生率有相关性。论文2月7日在线发表于《欧洲心脏杂志》(Eur Heart J)。此项研究共纳入4896例接受R-ZES置入的心梗患者,并评估DAPT中断与支架血栓形成(ST)和心

JACC:DES置入后DAPT患者临床出血率及支架血栓率分析

药物洗脱支架(DES)植入后双重抗血小板治疗的最佳时间(DAPT)尚不清楚。根据DES植入代数确定其风险和收益可能有所不同。 本研究的目的是对DAPT患者置入DES后的疗效和安全性进行评估。我们收纳了随机对照试验,评估对DES置入后DAPT治疗的最佳时间。短期双重抗血小板治疗(S-DAPT)被定义为按实验方案最短DAPT时期,长期双重抗血小板治疗(L-DAPT)被定义为按实验方案最长DAPT时期

JACC:药物洗脱支架后双联抗血小板治疗时间是否越长越好?

经皮冠状动脉介入术(药物洗脱支架DES)后进行双联抗血小板(DAPT)可以有效地预防支架内血栓形成。期间,阻止或中断DAPT会升高缺血风险,包括支架内血栓,尤其是在DES植入后的第一周内。然而,是不是进行DAPT时间越长越好呢?这个问题一直困扰着临床医生。因此,美国纽约西奈山伊坎医学院The Zena and Michael A. Wiener 心血管研究所的Gennaro Giustino博士等